New iron pill could ease anemia in pregnancy for thousands
NCT ID NCT07381426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial in Bangladesh will test whether ferric citrate, a different form of iron, works better and causes fewer stomach problems than the standard ferrous fumarate for pregnant women with moderate to severe iron deficiency anemia. 680 women aged 18-35 in their second trimester will take either ferric citrate once daily for 8 weeks or ferrous fumarate twice daily for up to 12 weeks. The main goal is to see how much hemoglobin levels improve after 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ferric citrate (an iron supplement)
What this could lead to
If it works, this could provide a better-tolerated iron supplement for pregnant women with anemia, potentially improving adherence and outcomes.
What could go wrong
This is a single-country open-label trial, so results may not apply everywhere. Gastrointestinal side effects are still possible with ferric citrate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dhaka Medical College
Dhaka, Bangladesh
Contact Phone: •••-•••-•••• Email: •••••@•••••